en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2023
vol. 98
 
Share:
Send email
Share:
abstract:
Original paper

Personalized multi-marker panel in the risk assessment of atopic dermatitis phenotypes in children

Volodymyr Dytiatkovskyi
1
,
Olexandr Abaturov
1
,
Victor Dosenko
2
,
Tetiana Drevytska
2
,
Tetiana Lapikova-Bryhinska
2
,
Nataliya Naumenko
3
,
Oksana Alifirenko
3

  1. Dnipro State Medical University, Dnipro, Ukraine
  2. Bogomoletz Institute of Physiology, Kyiv, Ukraine
  3. Allergy Centre, MNPE Clinical Hospital of the Emergency Medicine of Dnipro City Council, Dnipro, Ukraine
Pediatr Pol 2023; 98 (2): 116-122
DOI: https://doi.org/10.5114/polp.2023.128063
Online publish date: 2023/06/14
View full text Get citation
 
PlumX metrics:
Introduction
This paper reports the study of a combined genetic and biomarker panel for assessing the risk of development of different phenotypes of atopic dermatitis (AD) in children: alone and combined with other atopic disorders (AtD) – allergic rhinitis/rhino-conjunctivitis (AR/ARC) and bronchial asthma (BA). The aim was to establish a personalized diagnostic multi-marker panel for assessing the developmental risk of different AD phenotypes in children combining single nucleotide polymorphism (SNP) rs_7927894 filaggrin (FLG) genotype variants, serum levels of total immune globulin E (IgE), cutaneous T-cell attracting chemokine (CTACK/CCL27) and thymus and activation regulated chemokine (TARC/CCL17).

Material and methods
The study recruited patients aged 3–18 years old: 39 atopic patients to the main group and 47 non-atopic patients to the control group. All the patients were tested for SNP variants of rs_7927894 FLG and serum concentrations of total IgE, CTACK/CCL27 and TARC/CCL17.

Results
Within AD alone phenotype patients we detected the following significant risk ratios: cytosinethymine (C/T) rs_7927894 FLG [odds ratio (OR) = 4.14, p < 0.05], total IgE > 173 IU/ml (OR = 8.98, p < 0.001), CTACK/ CCL27 > 3658.5 pg/ml (OR = 5.64, p < 0.01). Atopic disorders combined with other AtD phenotype: C/T rs_7927894 FLG (OR = 2.88, p < 0.05), total IgE > 213 IU/ml (OR = 136.7, p < 0.001), CTACK/CCL27 > 4308.8 pg/ml (OR = 7.40, p < 0.001). With AD combined with other AtD collated to AD alone – total IgE > 1001 IU/ml (OR = 16.0, p < 0.001). TARC/CCL17 had no significant differences among main and control groups.

Conclusions
Cytosinethymine rs_7927894 FLG variant combined with cut-off serum IgE and CTACK/CCL27 levels is a novel significant personalized multi-marker panel for assessing the risk of development of the different AD phenotypes in children.

keywords:

filaggrin, total IgE, atopic dermatitis, CTACK/CCL27, TARC/CCL17